Message-ID: <29246925.1075845742138.JavaMail.evans@thyme>
Date: Thu, 7 Jun 2001 00:52:00 -0700 (PDT)
From: sylvia.hu@enron.com
To: clement.abrams@enron.com, jim.armogida@enron.com, sharon.butcher@enron.com, 
	drew.fossum@enron.com, kay.mann@enron.com, david.nutt@enron.com, 
	daniel.rogers@enron.com, rex.rogers@enron.com, 
	kriste.sullivan@enron.com, robert.vote@enron.com
Subject: FW: June 7 -- BNA, Inc. Antitrust & Trade Regulation Daily
Mime-Version: 1.0
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit
X-From: Sylvia Hu
X-To: Clement Abrams, Jim Armogida, Sharon Butcher, Drew Fossum, Kay Mann, David Nutt, Daniel R Rogers, Rex Rogers, Kriste Sullivan, Robert Vote
X-cc: 
X-bcc: 
X-Folder: \Kay_Mann_June2001_1\Notes Folders\All documents
X-Origin: MANN-K
X-FileName: kmann.nsf

User iD:  enronatd
PW:        bnaweb22


 -----Original Message-----
From:  "BNA Highlights" <bhighlig@bna.com>@ENRON 
[mailto:IMCEANOTES-+22BNA+20Highlights+22+20+3Cbhighlig+40bna+2Ecom+3E+40ENRON
@ENRON.com] 
Sent: Wednesday, June 06, 2001 11:07 PM
To: BNA Highlights
Subject: June 7 -- BNA, Inc. Antitrust & Trade Regulation Daily

__________________________________

ANTITRUST & TRADE REGULATION DAILY
Highlights
Thursday, June 7, 2001
__________________________________

ISSN 1526-520X

Registered Web subscribers can access the full text of these
articles by using the URL link supplied.

Information about becoming a subscriber or signing up for a
FREE Web trial is available at http://web.bna.com or call
BNA  Customer Relations at 1-800-372-1033, Mon. - Fri. 8:30
am - 7:00 pm (ET).
__________

HIGHLIGHTS
__________

SIXTH CIRCUIT AFFIRMS SUMMARY DISPOSITION OF UROKINASE CASE
IN UNPUBLISHED OPINION
The summary disposition of a Sherman Act Section 1 and
Section 2 attack on an exclusive supply contract for a raw
material used to produce urokinase, a broad category of
thrombolytics used for treating clinical conditions caused
by blood clots, is upheld in an unpublished opinion by the
U.S. Court of Appeals for the Fourth Circuit ("Microbix
Biosystems, Inc. v. BioWhittaker, Inc., "4th Cir., No.
00-2262, 6/4/01).

http://pubs.bna.com/ip/BNA/atd.nsf/id/A0A4G7D9H5_

COURT ENJOINS TUMS COMMERCIAL, FINDS CLAIM FOR RIVAL PRODUCT
TO BE LITERALLY TRUE
The manufacturer of Tums(R) may need to take a more costly
competing product as a result of a decision by the U.S.
District Court for the Southern District of New York, which
upholds a competitor's comparative advertising while
enjoining a Tums commercial as literally false in violation
of Lanham Act Section 43(a) ("SmithKline Beecham Consumer
Healthcare, L.P. v. Johnson & Johnson-Merck Consumer
Pharmaceuticals Co., "S.D.N.Y., No. 01 Civ. 2775 (DAB),
6/1/01).

http://pubs.bna.com/ip/BNA/atd.nsf/id/A0A4G7D9K4_

STATE REGULATORS OK, WITH CONDITIONS, ON VERIZON BID TO SELL
LONG-DISTANCE SERVICE
Regulators in Pennsylvania June 6 told Verizon Pennsylvania
they would support the phone company's planned application
to the Federal Communications Commission seeking to provide
long-distance services in the state, provided the company
meets several conditions.

http://pubs.bna.com/ip/BNA/atd.nsf/id/A0A4G7D9P9_

REGULATORY RECIPROCITY COULD OFFER SOLUTION TO COMPETITION
IN CANADIAN BANKING SECTOR
OTTAWA--Permitting foreign banks to do business directly in
Canada under the oversight of their home country regulators
would solve Canada's current problem of maintaining
sufficient competition in the retail banking sector,
according to a study released on May 29 by the C.D. Howe
Institute.

http://pubs.bna.com/ip/BNA/atd.nsf/id/A0A4G7D9R1_

__________
Antitrust & Trade Regulation Daily (ISSN 1526-520X)
Highlights are published daily by The Bureau of National
Affairs, Inc., 1231 25th St., NW, Washington, DC 20037.

For account information and changes, contact 1-800-372-1033
(M-F, 8:30 am-7:00 pm ET)

To request retransmission or to order a copy of the
summarized article, contact 1-800-452-7773 or e-mail
bnaplus@bna.com.

For copyright guidelines, go to
http://www.bna.com/corp/copyright.

Copyright (c) 2001 by The Bureau of National Affairs, Inc.
Washington, D.C.  20037.  Use of this service is subject to
the terms and conditions of the license agreement with BNA.
Unauthorized access or distribution is prohibited.